Flexion Therapeutics Keeps Climbing

21Vianet Group Inc NASDAQ: VNET, Ulta Salon, Cosmetics & Fragrance, Inc. NASDAQ: ULTA and Flexion Therapeutics Inc NASDAQ: FLXN are today's top-gaining billionaire stock picks midday. The biggest losers are North Atlantic Drilling Ltd. NYSE: NADL, Stemline Therapeutics Inc NASDAQ: STML and Ruckus Wireless Inc NYSE: RKUS.

Flexion Therapeutics

Flexion Therapeutics Surges Yet Again

The share price of 21Vianet Group Inc ( VNET) soared +24.68% this morning, rebounding from a major sell-off this week spurred by Ponzi scheme accusations made by Trinity Research Group. George Soros initiated a position in the Chinese internet company during the first quarter of this year, and Farallon Capital picked up a stake in Q2. Today's bounce comes as a relief to both parties, though this story is far from over.

Ulta Salon, Cosmetics & Fragrance, Inc. ( ULTA) climbed +19.82% after raising its guidance for the full fiscal year 2014 and getting a price target increase from Morgan Stanley to $121.00. Billionaire hedge fund manager Steve Mandel initiated a position in the beauty company in Q1 2012 and as of Q2 2014 holds 5.2 million ULTA shares.

Taking the third and final spot on today's list of midday gainers is Flexion Therapeutics Inc ( FLXN), up +7.54%. The Soros pick has had a stellar run this week, with its price climbing more than +45% over the past five days.

Russia Sanctions Take a Toll on North Atlantic Drilling

North Atlantic Drilling Ltd. ( NADL) dipped -7.33% early in the day this Friday following the admission of company CEO John Fredriksen this week that international sanctions against Russia may affect a deal with OCO Rosneft.

The share price of Stemline Therapeutics Inc ( STML) dropped -6.29% today. Despite today's dip, this week has been a strong one for the biopharmaceutical company thanks to increased earnings estimates and higher trading volumes. STML has climbed nearly +33% over the past five days.

Down -5.55% is Ruckus Wireless Inc ( RKUS), the third and final company on today's list of midday losers. Investment analysts at Buckingham Research have downgraded the stock from a buy to a neutral rating, and Morgan Stanley assumed coverage of the company, issuing an underweight rating and a $13.00 price objective. This George Soros pick is up a slight +1.41% YTD.

The post Flexion Therapeutics Keeps Climbing appeared first on ValueWalk.

-By iBillionaire

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

2 Biotechs That Could Flex Their Muscles

Biotech Movers: Ocular, Alder, Flexion

2 Recovering Biotech Names With Room to Run